AbbVie Inc. vs ASML Holding NV: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and ASML Holding NV across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating ASML Holding NV, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and ASML Holding NV is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $35.3B for ASML Holding NV, while their respective market capitalizations stand at $451.5B and $268.0B. AbbVie Inc. is headquartered in United States and ASML Holding NV operates from Netherlands, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

ASML Holding NV: ASML makes money by selling lithography systems and providing installed-base service, upgrades, software, and field options. Its EUV monopoly creates unusually high strategic importance within the global chip supply chain.

AbbVie Inc. and ASML Holding NV pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and ASML Holding NV.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

ASML Holding NV business model: Building one requires components sourced from more than 5,000 suppliers across 16 countries, assembled through a process so intricate that delivery, installation, and commissioning at a customer's fabrication plant takes months. EUV systems represent the apex of ASML's product portfolio and the locus of its pricing power. Instead, ASML sells performance upgrades — enhanced throughput, improved overlay accuracy, expanded process windows — as separately licensed software and hardware packages that customers purchase over the machine's operational lifetime. ASML's pricing power is extraordinary by any industrial standard, and it derives directly from the company's monopoly position. This allows ASML to maintain gross margins on EUV systems that consistently exceed 50 percent and to set pricing that reflects the extraordinary economic value the equipment creates for customers. The problem is, ASML captures a small but growing fraction of this value through its pricing. China's share of ASML's total revenue, which reached approximately 29 percent in the first half of 2023, has been progressively curtailed since the Dutch government declined to renew ASML's export license for EUV systems in 2019. Each new generation of EUV technology commands higher pricing, drives higher service revenue, and further widens the technological gap between ASML and any theoretical competitor.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of ASML Holding NV.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

ASML Holding NV competitive advantage: This service business is characterized by very high switching costs: a chipmaker cannot simply swap out lithography equipment mid-production without catastrophic disruption. The company's headquarters in Veldhoven, adjacent to the Dutch city of Eindhoven, reflects its roots in the Philips industrial ecosystem that made the southern Netherlands a European technology hub in the twentieth century. The physics challenges, the optical engineering requirements, and the supplier ecosystem limitations that China faces are not primarily financial obstacles; they are time and knowledge obstacles that money alone cannot solve on any commercially relevant timeline. ASML's competitive advantage is perhaps the most formidable in the global technology industry, resting on a combination of accumulated technological know-how, supplier ecosystem lock-in, customer switching costs, and regulatory moats that collectively make replication by any competitor — whether private, state-sponsored, or otherwise — extraordinarily difficult. The technological core of ASML's advantage is its mastery of EUV lithography, a technology that the company spent over 20 years and billions of dollars developing before shipping its first commercial EUV machine in 2017. The Carl Zeiss SMT relationship deserves particular emphasis as a competitive moat. ASML's customer relationships also create powerful demand-side moats. This technical advantage was real but not significant, and ASML spent its first several years fighting for every customer order, often competing on price to compensate for its lack of brand recognition.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and ASML Holding NV each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

ASML Holding NV growth strategy: ASML's growth strategy centers on EUV capacity, High-NA EUV adoption, installed-base service upgrades, deep supplier coordination, and long-term demand from leading-edge logic and memory customers.

A closer look at the financial trajectory of AbbVie Inc. and ASML Holding NV rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

ASML Holding NV: ASML reported EUR32.7B in FY2025 total net sales, EUR9.6B in net income, a 52.8% gross margin, and EUR38.8B of backlog at year-end. Using CorpDigest's USD convention, those figures are shown as about $35.3B of revenue and $10.4B of net income. The key financial drivers are EUV system demand, DUV resilience, installed-base services, High-NA adoption, and export-control limits.